The use of non-venous analytes has been a priority publichealth tool for the diagnosis, monitoring and surveillance of arange of pathogens. These methods, primarily based on DriedBlood Spots (DBS) and Gingival Crevicular Fluid (GCF), were firstdeveloped in the UK and have been applied to investigate outbreakand transmission events,1,2 to improve the diagnosis of infectionsin underserved populations3,4 in addition to monitoring infectiontrends and informing on the impact of interventions.5,6 The ability to use non-venous analytes for antigen, antibody and nucleic acid detection and characterisation has applications toanswer questions linked to SARS-CoV-2 infections. The virus has been shown to transmit efficiently between individuals and within communities,7–10 with the rapid spread of SARS-CoV-2 attributed to transmissions from asymptomatic but infected individuals.10–14The ease of sampling with non-venous analytes and the ability for self-collection allows for rapid and accessible individual and population-based diagnostics and monitoring of prevalence. The convenience and acceptability of sample collection permit population prevalence studies, for example in school children or in immunised self-isolating individual populations, providing an important mechanism for generating data for virus surveillance with a potential to inform policy. A key role of population antibody testing would be to characterise the relationship between the development and dynamics of antibody responses to infection, vaccination, and the impact of the measures on subsequent rates of transmission